Search Browse Earnings

UroGen Pharma Ltd.

Nasdaq:URGN

Pharmaceutical Preparations·RA'ANANA, L3

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$90.4M

+425.8% YoY

FY 2025

Adj. EBITDA

-$96.5M

-106.7% margin

FY 2025

Net Income

-$126.9M

-140.4% margin

FY 2025

EPS (Diluted)

-$2.96

FY 2025

Stock Price

$19.96

-2.4%

2026-03-09

52W Range

$3.42 – $30.00

P/E Ratio

-6.7x

Market Cap

$971.7M

Cash

$172.0M

FY 2025

Total Debt

$121.7M

FY 2025

Net Cash

$50.3M

FY 2025

Enterprise Value

$921.4M

Debt / EBITDA

0.5x

FY 2025

EV / EBITDA

-9.6x

Employees

—

CEO

Barrett Elizabeth A.

CFO

Degnan Chris